% | $
Quotes you view appear here for quick access.

tập đoàn Aradigm Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • CJL72 CJL72 Dec 21, 2010 4:24 PM Flag


    Note6. Collaborations and Royalty Agreements: Zogenix

    In August 2006, the Company sold all of its assets related to the Intraject needle-free injector technology platform and products, including 12 United States patents along with foreign counterparts, to Zogenix, Inc., a privately-held pharmaceutical company.
    Zogenix is responsible for further development and commercialization efforts of Intraject (now rebranded under the name DosePro).
    Under the terms of the asset sale agreement, the Company received a $4.0 million initial payment from Zogenix and was entitled to a $4.0 million milestone payment upon initial U.S. commercialization, as well as quarterly royalty payments in the amount of 3% of Net Sales of DosePro products.
    In December 2007, Zogenix submitted a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for the migraine drug sumatriptan using the needle-free injector DosePro (“SUMAVEL* DosePro”).
    The NDA was accepted for filing by the FDA in March 2008.
    The same month, Zogenix entered into a license agreement to grant exclusive rights in the European Union to Desitin Pharmaceuticals, GmbH to develop and commercialize SUMAVEL DosePro in the European Union.

7.40-0.20(-2.63%)Jul 2 3:59 PMEDT